NCT04886271 2026-04-15
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 2 Completed
Clinical Trials
154 trialsNCT04911907 2026-04-03
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Completed
NCT01761929 2026-03-06
5fr SBRT
University Health Network, Toronto
Phase 2 Completed
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT05661578 2026-02-09
SKYSCRAPER-11
Hoffmann-La Roche
Phase 2 Completed
NCT02662504 2026-02-05
MesoPDT
University Hospital, Lille
Phase 2 Completed
NCT05419375 2026-02-03
Screening Study for Participants With Malignant Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT04504942 2026-01-23
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
CytoDyn, Inc.
Phase 2 Completed
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT05388058 2026-01-16
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Mayo Clinic
Phase 2 Completed
NCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
NCT05014828 2025-08-24
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT00354393 2025-07-15
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
Phase 2 Completed
NCT02078700 2025-06-25
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
Phase 2 Completed
NCT01197885 2025-06-13
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT05455424 2025-05-15
NERO
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed
NCT04082572 2025-05-13
Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05963386 2025-03-28
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
The First Affiliated Hospital of Xiamen University
Phase 2 Completed
NCT04716634 2025-03-25
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT03560973 2025-03-13
RAMES
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT04177953 2025-02-06
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03477175 2025-01-07
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
Eisai Inc.
Phase 2 Completed
NCT02057380 2024-11-20
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Inc
Phase 2 Completed
NCT01265433 2024-10-09
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Phase 2 Completed
NCT05660616 2024-08-27
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
Phase 2 Completed
NCT03802123 2024-07-09
iCorrelate
ImaginAb, Inc.
Phase 2 Completed
NCT04480372 2024-07-01
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Swiss Cancer Institute
Phase 2 Completed
NCT03861156 2024-04-09
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
InventisBio Co., Ltd
Phase 2 Completed
NCT00445965 2024-04-04
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05041062 2024-01-03
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
Phase 2 Completed
NCT03274661 2023-10-19
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Baptist Health South Florida
Phase 2 Completed
NCT03253679 2023-10-17
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
National Cancer Institute (NCI)
Phase 2 Completed
NCT01827384 2023-09-29
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
National Cancer Institute (NCI)
Phase 2 Completed
NCT04521179 2023-09-21
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Completed
NCT04346381 2023-09-18
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT01486368 2023-08-04
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Phase 2 Completed
NCT02506517 2023-08-01
A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene
University Health Network, Toronto
Phase 2 Completed
NCT02899195 2023-07-05
PrE0505
PrECOG, LLC.
Phase 2 Completed
NCT00101283 2023-07-03
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05898451 2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2 Completed
NCT02426892 2023-04-18
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03616834 2023-03-22
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Effector Therapeutics
Phase 2 Completed
NCT04115111 2023-03-15
Diadem
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT02454972 2023-03-02
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
PharmaMar
Phase 2 Completed
NCT04169672 2023-03-02
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Hutchmed
Phase 2 Completed
NCT02293005 2022-10-04
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 2 Completed